EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Donor lymphocyte infusions as pre-emptive and therapeutic strategy for post-transplant acute lymphoblastic leukemia relapse: A retrospective single-center analysis on 16 consecutive patients

Fabio Serpenti, Cecilia Anna Fidanza, Riccardo Mario Colombo, Kordelia Barbullushi, Francesca Cavallaro, Nicola Cecchi, Mariarita Sciumè, Elena Tagliaferri, Maria Goldaniga, Nicola Stefano Fracchiolla, Francesco Onida, Francesco Passamonti und 1 weitere

Annals of Hematology · 04.11.2026

DOI: 10.1007/s00277-026-07345-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 04.11.2026. Verfasst von Fabio Serpenti und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the rapidly evolving landscape, allogeneic transplant still plays a role in acute lymphoblastic leukemia. Relapse post-transplant is not uncommon, leading to dismal prognosis. Donor lymphocyte infusions efficacy in this setting remains controversial. In this retrospective study, we report the use of DLIs in a cohort of 43 ALL (30 B- 13 T-) patients, treated at our Center between 2012 and 2024. 2y-OS, EFS and GRFS were 69.7% (57–85), 44.2% (31–63) and 34.9% (23–52). DLIs were administered in 16 patients. Indication were molecular relapse (44%), hematological relapse (37%) and mixed chimerism (19%). Patients received a median of 4 infusions (1–12), with the first being at a median of 218d (50-1076) post-transplant; median dose was 5.20 × 10^6 CD3+/kg (0.5–50). After DLIs, 2y-OS, EFS and GRFS were 68.8% (49–96), 41.2% (23–75) and 31.2% (15–65), respectively. 2y cumulative incidence of relapse post-DLI was 56.2%. Reasons for not administering DLI in other relapsed patients ( n = 9) were prior GvHD, logistical issues and rapid progression. Outcome was dismal for these patients with 2y-OS of 29.6% (10–87). Overall, our findings suggest that DLIs may retain a role in ALL, particularly when administered in the context of minimal disease burden and when integrated with emerging therapeutic approaches.

Zitieren

APA

Serpenti, F., Fidanza, C. A., Colombo, R. M., Barbullushi, K., Cavallaro, F., Cecchi, N., Sciumè, M., Tagliaferri, E., Goldaniga, M., Fracchiolla, N. S., Onida, F., Passamonti, F., & Saporiti, G. N. (2026). Donor lymphocyte infusions as pre-emptive and therapeutic strategy for post-transplant acute lymphoblastic leukemia relapse: A retrospective single-center analysis on 16 consecutive patients. Annals of Hematology. https://doi.org/10.1007/s00277-026-07345-x

Vancouver

Serpenti F, Fidanza CA, Colombo RM, Barbullushi K, Cavallaro F, Cecchi N, et al. Donor lymphocyte infusions as pre-emptive and therapeutic strategy for post-transplant acute lymphoblastic leukemia relapse: A retrospective single-center analysis on 16 consecutive patients. Annals of Hematology. 2026. doi:10.1007/s00277-026-07345-x

BibTeX
@article{Serpenti2026,
  author = {Serpenti, Fabio and Fidanza, Cecilia Anna and Colombo, Riccardo Mario and Barbullushi, Kordelia and Cavallaro, Francesca and Cecchi, Nicola and Sciumè, Mariarita and Tagliaferri, Elena and Goldaniga, Maria and Fracchiolla, Nicola Stefano and Onida, Francesco and Passamonti, Francesco and Saporiti, Giorgia Natascia},
  title = {Donor lymphocyte infusions as pre-emptive and therapeutic strategy for post-transplant acute lymphoblastic leukemia relapse: A retrospective single-center analysis on 16 consecutive patients},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-07345-x}
}
Kostenlos starten →